Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Brain Neoplasms drug therapy"" wg kryterium: Temat


Tytuł :
Imatinib is active in glioblastoma multiforme expressing platelet-derived growth factor receptor
Autorzy :
Fabiana Viola
Jaques Tabacof
Rene Cláudio Gansl
Rober Abramoff
Artur Katz
Carlos Henrique Barrios
Sergio Daniel Simon
Pokaż więcej
Temat :
Astrocytoma/drug therapy
Brain neoplasms/drug therapy
Glioblastoma/therapy
Piperazines/therapeutic use
Receptors
platelet-derived growth factor
Medicine
Źródło :
Einstein (São Paulo), Vol 6, Iss 2, Pp 115-119 (2008)
Opis pliku :
electronic resource
Relacje :
http://www.einstein.br/revista/arquivos/PDF/338-Einsteinv6n2p115-9.pdf; https://doaj.org/toc/1679-4508
Dostęp URL :
https://doaj.org/article/7192d9c5a181480e86232582ff16f2c3
Czasopismo naukowe
Tytuł :
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B
Autorzy :
Mikkel Staberg
Rikke Darling Rasmussen
Signe Regner Michaelsen
Henriette Pedersen
Kamilla Ellermann Jensen
Mette Villingshøj
Jane Skjoth‐Rasmussen
Jannick Brennum
Kristoffer Vitting‐Seerup
Hans Skovgaard Poulsen
Petra Hamerlik
Pokaż więcej
Temat :
Primary Cell Culture
Research Article
Lomustine/administration & dosage
Astrocytes/metabolism
histone demethylase
epigenetics
Research Support, Non-U.S. Gov't
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Apoptosis/drug effects
cancer stem‐like cell
Brain Neoplasms/drug therapy
F-Box Proteins/genetics
Cell Line
Glioblastoma/drug therapy
Neoplastic Stem Cells/metabolism
Lysine/metabolism
DNA Damage/drug effects
Antineoplastic Agents/administration & dosage
chemoresistance
glioblastoma
Drug Resistance, Neoplasm
Jumonji Domain-Containing Histone Demethylases/genetics
RC254-282
Histones/metabolism
Journal Article
Research Articles
Etoposide/administration & dosage
Humans
Źródło :
Molecular Oncology, Vol 12, Iss 3, Pp 406-420 (2018)
Staberg, M, Rasmussen, R D, Michaelsen, S R, Pedersen, H, Jensen, K E, Villingshøj, M, Skjoth-Rasmussen, J, Brennum, J, Vitting-Seerup, K, Poulsen, H S & Hamerlik, P 2018, ' Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B ', Molecular Oncology, vol. 12, no. 3, pp. 406-420 . https://doi.org/10.1002/1878-0261.12174
Opis pliku :
application/pdf
Tytuł :
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma
Autorzy :
Stupp, R.
Pavlidis, N.
Jelic, S.
Pokaż więcej
Temat :
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Brain Neoplasms/diagnosis
Brain Neoplasms/drug therapy
Brain Neoplasms/radiotherapy
Brain Neoplasms/surgery
Chemotherapy, Adjuvant
Diagnosis, Differential
Glioma/diagnosis
Glioma/drug therapy
Glioma/radiotherapy
Glioma/surgery
Humans
Incidence
Neoplasm Staging
Radiotherapy, Adjuvant
Risk Assessment
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology, vol. 16, no. Suppl 1, pp. i64-5
Opis pliku :
application/pdf
Tytuł :
Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)
Autorzy :
Wick, Wolfgang
Gorlia, Thierry
Bady, Pierre
Platten, Michael
van den Bent, Martin J
Taphoorn, Martin J B
Steuve, Jonathan
Brandes, Alba A
Hamou, Marie-France
Wick, Antje
Kosch, Markus
Weller, Michael
Stupp, Roger
Roth, Patrick
Golfinopoulos, Vassilis
Frenel, Jean-Sebastien
Campone, Mario
Ricard, Damien
Marosi, Christine
Villa, Salvador
Weyerbrock, Astrid
Hopkins, Kirsten
Homicsko, Krisztian
Lhermitte, Benoit
Pesce, Gianfranco
Hegi, Monika E
Pokaż więcej
Temat :
Clinic for Neurology
Clinic for Oncology and Hematology
Adult
Aged
Brain Neoplasms/drug therapy
Brain Neoplasms/mortality
Brain Neoplasms/radiotherapy
Chemoradiotherapy/methods
DNA Methylation
DNA Modification Methylases/genetics
DNA Repair Enzymes/genetics
Dacarbazine/administration & dosage
Dacarbazine/analogs & derivatives
Female
Glioblastoma/drug therapy
Glioblastoma/mortality
Glioblastoma/radiotherapy
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Promoter Regions, Genetic/genetics
Proportional Hazards Models
Sirolimus/administration & dosage
Sirolimus/analogs & derivatives
Tumor Suppressor Proteins/genetics
Young Adult
610 Medicine & health
Źródło :
Wick, Wolfgang; Gorlia, Thierry; Bady, Pierre; Platten, Michael; van den Bent, Martin J; Taphoorn, Martin J B; Steuve, Jonathan; Brandes, Alba A; Hamou, Marie-France; Wick, Antje; Kosch, Markus; Weller, Michael; Stupp, Roger; Roth, Patrick; Golfinopoulos, Vassilis; Frenel, Jean-Sebastien; Campone, Mario; Ricard, Damien; Marosi, Christine; Villà, Salvador; Weyerbrock, Astrid; Hopkins, Kirsten; Homicsko, Krisztian; Lhermitte, Benoit; Pesce, Gianfranco Angelo; Hegi, Monika E (2016). Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clinical Cancer Research, 22(19):4797-4806.
Clinical Cancer Research : An Official Journal of the American Association For Cancer Research 22(19) 4797-4806
Clinical cancer research, vol. 22, no. 19, pp. 4797-4806
Opis pliku :
application/pdf
Tytuł :
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan
Autorzy :
Urup, Thomas
Dahlrot, Rikke Hedegaard
Grunnet, Kirsten
Christensen, Ib Jarle
Michaelsen, Signe Regner
Toft, Anders
Larsen, Vibeke Andrée
Broholm, Helle
Kosteljanetz, Michael
Hansen, Steinbjørn
Poulsen, Hans Skovgaard
Lassen, Ulrik
Pokaż więcej
Temat :
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Bevacizumab/administration & dosage
Brain Neoplasms/drug therapy
Camptothecin/administration & dosage
Cohort Studies
Disease-Free Survival
Female
Follow-Up Studies
Glioblastoma/drug therapy
Humans
Irinotecan
Male
Middle Aged
Models, Biological
Neoplasm Recurrence, Local/drug therapy
Prognosis
Retrospective Studies
Young Adult
Źródło :
Urup, T, Dahlrot, R H, Grunnet, K, Christensen, I J, Michaelsen, S R, Toft, A, Larsen, V A, Broholm, H, Kosteljanetz, M, Hansen, S, Poulsen, H S & Lassen, U 2016, ' Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan ', Acta Oncologica, vol. 55, no. 4, pp. 418-422 . https://doi.org/10.3109/0284186X.2015.1114679
Tytuł :
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter - still a dilemma?
Autorzy :
Hegi, Monika E.
Stupp, Roger
Pokaż więcej
Temat :
Antineoplastic Agents/therapeutic use
Brain Neoplasms/drug therapy
Brain Neoplasms/genetics
DNA Methylation/genetics
DNA Modification Methylases/genetics
DNA Repair Enzymes/genetics
Dacarbazine/analogs & derivatives
Dacarbazine/therapeutic use
Glioblastoma/drug therapy
Glioblastoma/genetics
Humans
Promoter Regions, Genetic/genetics
Tumor Suppressor Proteins/genetics
Clinic for Oncology and Hematology
610 Medicine & health
Editorials
Źródło :
Hegi, Monika E; Stupp, Roger (2015). Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter - still a dilemma? Neuro-Oncology, 17(11):1425-1427.
Neuro-oncology, vol. 17, no. 11, pp. 1425-1427
Opis pliku :
application/pdf
Tytuł :
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways
Autorzy :
Ho, SWA
Pu, JKS
Day, PJR
Lui, WM
Fung, CF
Lee, D
Sun, S
Zhang, X
Leung, GKK
Lee, NPY
Pokaż więcej
Temat :
Antineoplastic Agents, Alkylating/pharmacology
nervous system diseases
Blotting, Western
Basic and Translational Investigations
Brain Neoplasms/drug therapy
Animals
Apoptosis/drug effects

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies